Andrea Kocharyan
Private Equity Investor at Flagship Pioneering
Profile
Andrea Kocharyan is Vice President, Senior Counsel and Head of Contracts for Flagship Pioneering.
She joined Flagship in 2022, and leads the Flagship Contracts team, participates as the corporate legal representative to Flagship General Partner Avak Kahvejian’s origination team, and works closely with the real estate group on leases and related matters.
Andrea’s experience in the pharmaceutical industry spans more than 20 years and includes work in legal and in scientific roles.
Most recently, Andrea served as Vice President, Head of Legal and Chief Compliance Officer at Zealand Pharma US, Inc., a biotechnology company focused in metabolic and gastrointestinal diseases.
She was previously the Head of Legal at Sumitomo Dannipon Pharma Oncology, US General Counsel at rEVO Biologics, and held attorney roles at Biogen, Ironwood, and Forum Pharmaceuticals.
Andrea began her career as a laboratory associate with roles at Genzyme and Biogen.
Andrea has been an annual presenter at the CBI Specialty Pharmaceutical Compliance Congress from 2016-2021, where she served as the conference chair in 2021.
She has been a speaker at the Women Leaders in Life Sciences conference in Boston as well as the annual Pharmaceutical Compliance Forum and Pharmaceutical Compliance Congress in Washington D.C.
Andrea holds a J.D.
from Suffolk University Law School and a B.S.
in Biology from Worcester Polytechnic Institute.
Andrea Kocharyan active positions
Companies | Position | Start |
---|---|---|
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Private Equity Investor | 2022-07-31 |
Former positions of Andrea Kocharyan
Companies | Position | End |
---|---|---|
ZEALAND PHARMA A/S | Private Equity Investor | 2022-07-31 |
Sumitomo Dainippon Pharma Oncology, Inc.
Sumitomo Dainippon Pharma Oncology, Inc. BiotechnologyHealth Technology Part of Sumitomo Chemical Co., Ltd., Sumitomo Dainippon Pharma Oncology, Inc. is a developer of novel cancer therapeutics. The company is based in Cambridge, MA. The company has teams in the US and Japan and is relentlessly committed to advancing purposeful science by transforming new discoveries into meaningful treatments for patients with cancer. Sumitomo Dainippon Pharma Oncology is a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. The company has a diverse and purposeful pipeline of targeted therapies. The CEO of the company is Patricia S. Andrews. | Private Equity Investor | 2020-07-31 |
REVO BIOLOGICS INC | Private Equity Investor | 2017-04-30 |
Training of Andrea Kocharyan
Suffolk University Law School | Graduate Degree |
Worcester Polytechnic Institute | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
ZEALAND PHARMA A/S | Health Technology |
Private companies | 3 |
---|---|
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Sumitomo Dainippon Pharma Oncology, Inc.
Sumitomo Dainippon Pharma Oncology, Inc. BiotechnologyHealth Technology Part of Sumitomo Chemical Co., Ltd., Sumitomo Dainippon Pharma Oncology, Inc. is a developer of novel cancer therapeutics. The company is based in Cambridge, MA. The company has teams in the US and Japan and is relentlessly committed to advancing purposeful science by transforming new discoveries into meaningful treatments for patients with cancer. Sumitomo Dainippon Pharma Oncology is a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. The company has a diverse and purposeful pipeline of targeted therapies. The CEO of the company is Patricia S. Andrews. | Health Technology |
rEVO Biologics, Inc.
rEVO Biologics, Inc. BiotechnologyHealth Technology rEVO Biologics, Inc. engages in the development and commercialization of specialty therapeutics to address unmet medical needs in patients with rare, life-threatening conditions. Its products include ATryn, which prevents blood clots during and after surgery and childbirth for patients with hereditary antithrombin deficiency. The company was founded in February 1993 and is headquartered in Framingham, MA. | Health Technology |
- Stock Market
- Insiders
- Andrea Kocharyan